Overall rank by patents
#46,448
Across all tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, active 2021–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY).
The verdict
Epitech holds 5 US patents across 3 technology areas, rank #46,448 of 50,000 tracked assignees.
Epitech MAG Ltd. has been granted 5 US utility patents between 2021 and 2024, placing Epitech MAG Ltd. at rank #46,448 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.0 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a Foreign Corporation, Epitech MAG Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Epitech sits between EPIC Medical PTE. Ltd. (5 patents, rank #46,444) and Ernst GROB Ag (5 patents, rank #46,452) - the closest US assignees by grant volume. The composite Innovation Score of 31.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2021 through 2024, with 5 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Epitech MAG Ltd.'s 15.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Epitech MAG Ltd. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
EPIC MEDICAL PTE. LTD.
5 patents
EPIC SCIENCES, INC.
5 patents
EPIGAN NV
5 patents
EPIMMUNE INC.
5 patents
EQUUS UK TOPCO LTD
5 patents
ERA3 LLC
5 patents
ERGO EXERGY TECHNOLOGIES INC.
5 patents
ERNST GROB AG
5 patents
EPITECH MAG LTD.
5 patents
What this shows Epitech holds 5 patents at rank #46,448, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #46,448 in granted patent volume.
Other assignees with the most granted patents in Epitech's primary technology class.
Epitech's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
31 Top 63% higher than 37% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 2 | 40.0% |
| 2022 | 1 | 20.0% |
| 2024 | 2 | 40.0% |
Top 3 of 3 technology areas
Overall rank by patents
#46,448
Across all tracked assignees
31.3 out of 100
How to use this portfolio
Epitech's 5 grants land it in the top 63% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.